[Special Stock] CorelineSoft Surges on AI Software FDA Approval News in the US

Coreline Soft is showing strong performance following the news that its AI (artificial intelligence) software product has passed the safety verification by the U.S. Food and Drug Administration (FDA).

As of 10:30 AM on the 25th, Coreline Soft is trading at 7,470 KRW, up 21.46% (1,320 KRW) from the previous trading day.

The medical AI company Coreline Soft announced that it has obtained the premarket certification 'FDA 510(k) clearance' from the U.S. FDA for its AI software 'AVIEW'. The newly certified AVIEW 2.0 version features enhanced technology integration optimization, accessibility, security, and stability compared to the previous product.

The FDA 510(k) clearance is an approval system where the FDA verifies the performance and safety by comparing with previously certified products. It is a mandatory gateway for companies aiming to supply AI products within the U.S. Coreline Soft has received a total of 11 FDA certifications, including the first FDA clearance in 2018 for its AI-based integrated product suite AVIEW.

Jinkook Kim, CEO of Coreline Soft, stated, "As inquiries for Coreline Soft AI software adoption are rapidly increasing in the global market, we will strengthen our overseas market expansion through the new FDA certification." He added, "In particular, as we are enhancing cooperation with 3DR Labs, the largest medical imaging solution company in the U.S. starting this year, we plan to promote additional AI software supply to the company based on the newly acquired FDA certification."